Warning letterPosted February 24, 2026
FDA warning letter to MedisourceRx
Compounding Pharmacy/Adulterated Drug Products
FDA posted a warning letter to MedisourceRx on February 24, 2026; the letter is dated December 12, 2025. Subject: Compounding Pharmacy/Adulterated Drug Products. Issuing office: Center for Drug Evaluation and Research (CDER).
On the record
- Company
- MedisourceRx
- Subject
- Compounding Pharmacy/Adulterated Drug Products
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Letter dated
- 2025-12-12
- Posted by FDA
- 2026-02-24
- Source
- FDA warning letters ↗
CFR cited
The record cites 2 sections of 21 CFR Parts 201 and 310.
The full record
An account shows the violations FDA described and each CFR section it cited.
What a warning letter is
A warning letter is FDA's notice to a company that it found significant violations of federal requirements. FDA asks for a written response, normally within 15 working days. The letter is advisory: it states the agency's position and is not a final agency action.
More
Watch MedisourceRx
A free account shows the last 7 days of every FDA, SEC and ClinicalTrials.gov source. Pro adds a watchlist: one email when FDA acts on a company you name.
From FDA warning letters. The record may have changed since it was read.
Approve Suite is not affiliated with FDA, or with MedisourceRx. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.